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Abstract: BACKGROUND: We investigated the differential effectiveness of a stepped and collaborative
care model (SCM) vs. treatment as usual (TAU) for primary care patients with various depression severity
degrees and explored whether subgroups received distinct evidence-based treatments. METHODS: Sub-
group analyses of a RCT were calculated applying a multiple linear mixed model with the factors 1. group
(SCM; TAU), 2. severity ((mild-moderate (MMD); severe depression (SD)) and their interaction, with
PHQ-9 as primary outcome. Utilization of treatments was analyzed descriptively. RESULTS: For the 737
participating patients (SCM: n = 569; TAU: n = 168), availability of data substantially varies between
subgroups at 12-month follow-up ranging between 37% and 70%. ITT-analysis (Last-observation-carried-
forward) revealed a significant interaction for group x severity [p = 0.036] and a significant difference
between groups in symptom reduction for MMD (-3.9; [95% CI: -5.1 to -2.6, p < 0.001; d = 0.64] but
not for SD (-1.6; [95% CI: -3.4 to 0.2, p = 0.093; d = 0.27]. Sensitivity analyses (multiple imputation,
completer analysis, pattern mixture model) didn‘t confirm the interaction effect and showed significant
effects for both severity groups with slightly higher effect sizes for MMD. Differences between SCM and
TAU in the percentage of patients utilizing depression-specific treatments are larger for MMD. LIMITA-
TIONS: There was a high proportion of missing values among severely depressed patients, especially in
SCM. CONCLUSION: SCM is effective for both MMD and SD. Utilization patterns might help explain
the higher effects for MMD. Various strategies of replacement of missing values lead to slightly divergent
results due to selective drop out between severity groups.
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 SCM is effective for both mildly to moderately and severely depressed patients 
 Effects are higher for mildly to moderately depressed patients 
 Special attention must be paid to severely depressed patients 
 SCM patients more often received outpatient depression-specific treatment 
 Difference in treatment utilization is higher for not severely depressed patients 
Abstract 
Background: We investigated the differential effectiveness of a stepped and collaborative care model (SCM) vs. treatment 
as usual (TAU) for primary care patients with various depression severity degrees and explored whether subgroups re-
ceived distinct evidence-based treatments. 
Methods: Subgroup analyses of a RCT were calculated applying a multiple linear mixed model with the factor 1. group 
(SCM; TAU), 2. severity ((mild-moderate (MMD); severe depression (SD)) and their interaction, with PHQ-9 as primary 
outcome. Utilization of treatments was analyzed descriptively. 
Results: For the 737 participating patients (SCM: n=569; TAU: n=168), availability of data substantially varies between 
subgroups at 12-month follow-up ranging between 37% and 70%. ITT-analysis (Last-observation-carried-forward) re-
vealed a significant interaction for group x severity [p=0.036] and a significant difference between groups in symptom re-
duction for MMD (-3.9; [95% CI: −5.1 to −2.6, p < 0.001; d=0.64] but not for SD (-1.6; [95% CI: −3.4 to 0.2, p = 0.093; 




tion effect and showed significant effects for both severity groups with slightly higher effect sizes for MMD. Differences 
between SCM and TAU in the percentage of patients utilizing specific treatments are larger for MMD. 
Limitations: There was a high proportion of missing values among severely depressed patients, especially in SCM. 
Conclusion: SCM is effective for both MMD and SD. Utilization patterns might help explain the higher effects for MMD. 
Various strategies of replacement of missing values lead to slightly divergent results due to selective drop out between s e-
verity groups. 
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Abbreviations 
SCM, Stepped and Collaborative Care Modell; TAU, Treatment as usual; RCT, Randomized controlled trial; MMD, mild to 
moderate depression; SD, severe depression; ITT, Intention to treat; CI, Confidence interval; ICD-10, International Statis-
tical Classification of Diseases and Related Health Problems; DSM, Diagnostic and Statistical Manual of Mental Disorders; 
CBT, cognitive behavioral therapy; CCBT, computerized cognitive behavioral therapy; GP, General practitioner; LOCF, last-
observation carried forward; MI, multiple imputation; AD, antidepressant treatment; PT, psychotherapeutic treatment 
1. Introduction 
Depression is one of the most common mental disorders. It is a very broad diagnostic category which can be divided into 
several subtypes of depression (DGPPN et al., 2015; Kessing, 2007; Kessler et al., 2003; NICE, 2010; Wittchen et al., 2000). The 
International Statistical Classification of Diseases and Related Health Problems (ICD-10) and the Diagnostic and Statistical Manual 
of Mental Disorders (DSM) differentiate mild, moderate and severe depression (American Psychiatric Association, 2013; Dilling et 
al., 2014). The ICD-10 additionally distinguishes between recurrent disorders and single episodes (Dilling et al., 2014). The differ-
entiation into the subtypes of depression with regard to severity, duration and course is not only important for how depression 
presents clinically, but also for guideline-adherent decision-making regarding evidence-based treatments (DGPPN et al., 2015; 
NICE, 2010): international guidelines recommend providing active monitoring to patients with subthreshold depression or pa-
tients with mild depression as first step. Patients with mild to moderate depression or persistent subthreshold depressive symp-
toms should be offered low intensity treatments like bibliotherapy, individual guided self-help based on the principles of cognitive 
behavioral therapy (CBT), computerized cognitive behavioral therapy (CCBT), or physical activity programs. Either medication or 
psychotherapy should be offered to patients with mild to moderate depression or persistent subthreshold depressive symptoms 
who did not benefit from low intensity treatments. For severely depressed patients, a combination of medication and psycho-
therapy is recommended; in cases of severe and complex depression, this combined treatment should be offered regularly, some-
times also in an inpatient treatment setting if patients do not improve in outpatient care (DGPPN et al., 2015; NICE, 2010). 
As there are distinct recommendations for different groups of depressed patients which vary in treatment intensity, a sys-
tematic treatment selection applying a stepped and collaborative care approach is crucial. While stepped care focuses on treating 
patients with an adequate treatment of the lowest possible intensity while continuously monitoring progress, collaborative care 
aims to systematically integrate different care providers. Both health care models are often combined and recommended by in-
ternational depression guidelines (DGPPN et al., 2015; Landelijke Stuurgroep, 2005; NICE, 2010). 
However, guideline implementation is still insufficient. Often patients with mild depression are over-prescribed with anti-
depressant medication (Baer et al., 2013; Trautmann and Beesdo-Baum, 2017), while patients with severe depression often do 
not receive the intensity of care they would need (Melchior et al., 2014). For the patients` sake but also from a cost-effectiveness 
perspective it would be relevant to prevent inpatient treatment by offering adequate outpatient treatment options at an early 




There is good evidence for the general effectiveness and partially also for the cost-effectiveness of SCM for depression 
(Archer et al., 2012; Firth et al., 2015; Goorden et al., 2014; Härter et al., 2018; Ho et al., 2016; van Straten et al., 2015; Von Korff 
et al., 1997). However, there is still little knowledge and evidence about differential effects of these models, i.e. whether there are 
characteristics of the patient or the type of the depression predicting the response to SCM. Since SCM comprises a complex inter-
vention that is tailored individually for patients, in the differential analysis of effects treatment variables have also to be taken 
into account, i.e. the type of treatments actually received by patients. These analyses of individual treatment utilization and 
treatment pathways may help explain (variations in) outcome effects. 
Even though it is known that depression severity degree is one of the best predictors of treatment response (Katon et al., 
1994; Walker et al., 2000), only few studies report results of SCM referring to different severity subgroups. One SCM intervention 
showed a significant improvement in depressive symptoms after 6 and 28 months compared with usual care for the group of 
moderately depressed patients, but not for patients in the high severity group (Katon et al., 2002; Walker et al., 2000). In a SCM 
for depression in the Netherlands, Franx and colleagues found that patients in the non-severe depression group were treated 
according to the guideline oriented SCM protocol considerably more often than severely depressed patients. Furthermore, the 
adherence to the SCM improved during the study for the non-severe group, but not for the severe group. They concluded that 
special attention should be paid to the quality of care for severely depressed patients (Franx et al., 2009). However, another study 
reported that health care consumption increased significantly in both depressed patient groups (Gidding et al., 2014). In accord-
ance with this, Unützer and colleagues did not find a significant interaction between intervention effect and depressive symptom 
severity (Unützer et al., 2002). In summary, no conclusive answer to this research question exists yet. 
1.1. Aims of the study 
Against this background, this article examines whether patients with different degrees of depression severity benefit dif-
ferentially from stepped and collaborative care and whether they differ in the treatments received, taking into account severity 
degree. The general effectiveness of the model under investigation has been already reported elsewhere (Härter et al., 2018), 
while the present analyses combine subgroup analyses with the treatment utilization of the subgroups. 
2. Methods 
2.1 Study design 
This parallel cluster-randomized controlled intervention trial assessed a consecutive sample of patients with depression 
from primary care with measurements at four time points (baseline and 3, 6 and 12 months after baseline). Randomization was 
conducted at the level of participating GP practices, dividing these into an intervention group and a control group in a 3:1 ratio. 
Patients recruited by GPs in the intervention group were treated in the stepped and collaborative care model (SCM), while pa-
tients recruited by GPs in the control group received treatment as usual (TAU). The process of randomization was conducted by a 
computer program using minimization based on practice size, practice location and income level of the practice’s local district 
(Watzke et al., 2014). 
Sample size calculation was based on the detection of a small to moderate effect (Cohen's d of 0.40) with a statistical pow-
er of 0.80 and a type I error rate of 0.05 (two sided) between SCM and TAU. After considering the clustered design with an as-
sumed intra-cluster correlation of 0.05, the differential expected attrition rates between groups, and the plan to run further sepa-
rate analyses for each of six treatment options, which are available in SCM (see section “2.5 Intervention”), we aimed to recruit a 
total of 860 patients. Expecting that every participating GP practice would recruit 15-25 patients, we planned to gain 40 practices 
for study participation (660 patients from 30 practices in SCM and 200 patients from 10 practices in TAU). In total, we recruited 49 




The study was approved by the Ethics Committee of the Hamburg Chamber of Psychotherapists and conducted according 
to the principles of the Declaration of Helsinki (2013 version). Written informed consent was obtained from all participants. The 
study was registered in ClinicalTrials.gov (registration number: NCT01731717; registration date: 11.12.2012). 
2.2 Setting 
The study “Health Network Depression” was embedded into the intersectoral research initiative psychenet - The Hamburg 
Network for Mental Health (2011-2015; funded by the German Federal Ministry of Education and Health) which consisted of 11 
research and development projects on mental health care research in the metropolitan area of Hamburg (Germany)(Härter et al., 
2012; Watzke et al., 2014). Patient assessment and treatment in SCM took place within a multi-professional, specially established 
and trained network of GP practices, psychotherapists, psychiatrists and inpatient clinic representatives implemented in routine 
care (Härter et al., 2015; Heddaeus et al., 2015), while assessment and treatment in TAU was conducted in GP practices as well as 
any facilities available in routine care. 
2.3 Care Providers 
All GP practices, psychotherapists, psychiatrists of the greater Hamburg area were invited by mail via the Hamburg Cham-
ber of Physicians to participate in the study. Inclusion criteria for participation were willingness to participate in study procedures 
and to be working as a Statutory Health Insurance GP, psychotherapist or psychiatrist in an established practice. For inpatient 
institutions inclusion criteria were willingness to participate in study procedures and to have a license from the Association of 
Statutory Health Insurance. 
2.4 Patients 
Patient recruitment in SCM and TAU was carried out by the participating GPs and comprised three screening and assess-
ment steps using checklists and the PHQ-9, successively (Watzke et al., 2014). Inclusion criteria were a minimum age of 18, five or 
more points on PHQ-9 and informed consent. Patients with insufficient knowledge of the German language or a health situation 
that did not allow questionnaire completion were excluded. Neither somatic nor mental comorbidities were exclusion criteria. 
Patients were only excluded if a mental disorder other than depression, e.g. a trauma-related disorder, was the main treatment 
focus. Patient inclusion took place from August 08, 2012 to March 31, 2014. Follow-up measurements took place between 2012 
and 2015. 
2.5 Interventions 
2.5.1 Stepped collaborative care model (SCM) 
The SCM is a stratified stepped and collaborative care approach which has been described in detail elsewhere (Watzke et 
al., 2014). GPs of the intervention group, i.e. GPs offering their patients SCM, completed an ICD-10-based checklist and imparted 
psycho-education if patients fulfilled the study criteria (PHQ-9 ≥ 5). Treatment interventions according to SCM were allocated by 
the GPs on the basis of the ICD-10 diagnosis following the evidence-based recommendations of the German National Clinical Prac-
tice Guideline “Unipolar Depression”(Watzke et al., 2014), i.e. criteria were: 1) depression severity and 2) patient preferences as 
result of a shared decision-making process. 
Within the SCM, treatment options were available on four levels of intensity: Step 1) active monitoring; 2a) bibliotherapy 
(Görlitz, 2010); 2b) internet-based self-management (Meyer et al., 2009); 2c) telephone-administered psychotherapy (9-13 ses-
sions)(Steinmann et al., 2016); 3a) outpatient cognitive-behavioral or psychodynamic psychotherapy (usually ≥ 25 sessions) as 




macotherapy in either out- or inpatient setting. Therefore, there were six treatment options (step 2-4) within the SCM – consider-
ing Step 1 (“active monitoring”) as an antecedent option and not as actual treatment option. 
Course of treatment and symptoms was monitored by care providers with the PHQ-9 in predefined intervals depending 
upon intervention and symptoms. If the PHQ-9 score had not improved by at least 20% since beginning a treatment, stepping up 
was recommended. A care provider network was built up to facilitate communication and prompt referral between primary and 
secondary care. To improve referral and to reduce waiting times, an online platform indicating available treatment capacities was 
implemented. All participating multi-professional providers obtained intensive training regarding the relevant guideline recom-
mendations (DGPPN et al., 2015; NICE, 2004), the SCM and its related interventions. Quarter-yearly quality circles took place to 
assure the quality of the integrated care model and a stable adherence to clinical recommendations. 
2.5.2 Treatment as usual (TAU) 
Patients in the TAU received treatment as usual by their GP and within the regular German health care system, including 
potentially necessary referrals to psychotherapy and psychiatry in out- or inpatient care settings. Systematic screening was carried 
out in both SCM and TAU to ensure a comparable recruitment and inclusion process. 
2.6 Outcomes 
All outcomes were assessed by self-report questionnaires at four time points: The baseline (T0) assessment was handed 
out by the GP at study inclusion and filled out before any treatment began. The questionnaires 3 (T1), 6 (T2) and 12 months (T3) 
after baseline were sent to patients by mail. If a questionnaire was not returned within two weeks, up to two reminder letters 
were sent to the patient and one to the patient’s GP within the following month to improve response rates. 
Primary outcome was change in depressive symptoms assessed by the Patient Health Questionnaire-9 (PHQ-9)(Löwe et al., 
2004) from baseline to 12 months (differential treatment outcome). Treatment utilization during the 12 months of study partici-
pation was assessed by patient self-report questionnaires at T1, T2 and T3. Patients retrospectively reported their use of different 
treatment options and consultation of various care providers. 
2.7. Statistical analysis 
The outcome analysis regarding change in PHQ-9 from baseline to T3 was based on the intention to treat (ITT) population. 
Only this time point was part of our analysis. In case of missing follow-up values, a last-observation carried forward (LOCF) impu-
tation was performed using also the time points in between for the imputation (primary analysis)(Watzke et al., 2014). As drop-
outs were distributed unequally, three kinds of sensitivity analyses were performed: One model using the ITT population and the 
multiple imputation (MI) replacement method instead of LOCF and a second one without LOCF replacement but with only those 
cases who provided data for the main outcome at T3 (i.e. completer analyses). To account for a possible violation of the missing at 
random assumption, we used a pattern mixture model with control-based pattern imputation as a third sensitivity analysis 
(Ratitch et al., 2013). 
For the subgroup analysis, we divided patients in both conditions into two groups of different depression severity: mild to 
moderate depression severity (averaged PHQ-9-score of less than 15) and severe depression severity (averaged PHQ-9-score of 15 
or more). We calculated a multiple linear mixed model with group (SCM vs TAU), depression severity (mild-moderate vs. severe), 
their interaction and education level as fixed effects (due to differences at baseline in this variable, cp. Table 1) and the general 
practice care unit as a random effect. We fitted a random intercept model with a scaled identity covariance matrix. We reported 





The differential treatment utilization of the two groups was analyzed descriptively. The analysis of treatment utilization is 
based on the sample of patients for which T3 data (including information on treatment utilization during the whole observation 
period of 12 months) is available (see also 3.3.2). The following hypotheses regarding differences in treatment utilization were 
derived from the stepped care model: In both severity groups (MMD und SD) it was expected that SCM was associated with fewer 
patients being treated with nothing besides GP consultations, as well as to a higher utilization of depression-specific treatments. 
For MMD, SCM was expected to result in the utilization of low intensity treatments, more psychotherapeutic treatment, less anti-
depressant (AD) treatment (as AD is not the first line treatment for mild depression) and less inpatient treatment than TAU. For 
severe depression, SCM was expected to be associated with more psychotherapeutic treatment (PT), more AD treatment, and 
more combination of PT and AD. 
All analyses were conducted with SPSS 23 and SAS 9.4. 
3. Results 
3.1. Participant flow 
Figure 1 shows the participant flow. 737 patients were included (SCM: n = 569 vs. TAU: n = 168), with data available for 
60% of SCM patients and 64% of TAU patients after 12 months. In SCM, 67% of patients (n=383) had a PHQ-9 score of less than 15 
points (mild to moderate depression (MMD)). In TAU this was the case for 67% (n=113). The severe depression group (SD) in SCM 
consisted of n=186 (33%) and in TAU of n=55 patients (33%). After baseline assessment, 46% of SD patients in SCM and 31% in 
TAU dropped out. For MMD, this rate was lower, with 11% of patients in SCM and 14% in TAU dropping out. At T3, 70% of the 
data of the MMD group were available in both SCM and TAU. In the SD group, 53% of the data were available in TAU and 37% in 
SCM. 
3.2. Sample 
Table 1 shows the baseline characteristics of patients in the four subgroups. 
3.3. Differential treatment outcome 
3.3.1. Primary analysis 
The LOCF-analysis of the adjusted PHQ-9 mean reduction from baseline to 12 months revealed a significant interaction be-
tween group and depression severity [p=0.036] (Table 2). Symptom reduction on the PHQ-9 for MMD was -6.2 points in the SCM 
and -2.4 points in TAU. For SD, symptom reduction on the PHQ-9 was -2.6 in SCM and -1.0 points in TAU. With a difference of 3.9 
points in the PHQ-9, the MMD group in SCM showed a significantly greater reduction in PHQ-9 scores than patients in TAU [95% 
confidence interval (CI): −5.1 to −2.6, p < 0.001; Cohen’s d=0.62+. For the SD group, the difference between SCM and TAU (a symp-
tom reduction of 1.6 points) was not significant *95% CI: −3.4 to 0.3, p = 0.093; Cohen’s d=0.25+. 
3.3.2 Sensitivity analyses 
Table 2 also summarizes the results of the three different model calculations for the sensitivity analyses (ITT analyses with 
MI replacement method and completer analyses and pattern mixture model with control-based pattern imputations). For all 
forms of analyses, an interaction between group and severity was not confirmed. The difference in symptom reduction between 




3.4. Differential treatment utilization 
Table 3 summarizes the observed proportions of treatments patients received during the 12 months of study participation 
and the comparison between SCM and TAU in total and differentiated for severity groups. 
GP consultation. As recruitment took place in primary care, nearly all patients in SCM and TAU were seen by their GP (90.6 
% and 96.3 % respectively). However, patients with TAU more often received nothing besides GP consultation, compared to pa-
tients in SCM (20.4 % vs. 3.5 %). Differentiated by severity subgroups, it becomes clear that this difference can be traced to the 
MMD group (25.3 % TAU patients vs. 3.7% SCM patients with GP consultation only), whereas for the SD group the percentage is 
low in both conditions. 
Any outpatient depression-specific treatment. The utilization of outpatient depression-specific interventions (a global cate-
gory summarizing low intensity-treatments, psychotherapy and pharmacotherapy) is in line with this. Here, there is a different 
utilization pattern of 16.9% between TAU and SCM. Differentiated by severity groups, this difference can also be traced to the 
MMD group (72.2% TAU patients vs. 94.4% SCM patients with depression-specific treatment), whereas for the SD group more 
than 93% of the patients in both conditions received this kind of treatment. This pattern results in a 20% greater difference be-
tween SCM and TAU for MMD than for SD (22.2% vs. 2.6%). 
Low intensity treatments. Low intensity treatments which were only offered in SCM (telephone psychotherapy, internet 
self-help, and bibliotherapy) were utilized by more than 40% of SCM patients (43.7% in MMD and 30.4% in SD). 20.7% of MMD 
patients utilized this form of intervention exclusively, i.e. without receiving a more intensive treatment in addition. In the SD 
group, there is a percentage of 15.9% of patients utilizing only low intensity treatments. 
Psychotherapy. For the global category, i.e. psychotherapy alone or in combination, there is a difference in utilization of 
13.4% between TAU and SCM. Differentiating for severity groups, this difference is higher for MMD (16.6%) than for SD (6.0%): 
Accordingly, psychotherapy is initiated for 45.6% of MDD patients in TAU, while in the other three groups the utilization rate is 
62% or higher. However, confidence intervals for these comparisons (total and MMD patients) overlap slightly. 
For the subgroup of patients receiving psychotherapy only and for the subgroup receiving psychotherapy and antidepres-
sant medication, no differences in utilization between groups was found. Since there is no difference for these treatment utiliza-
tion patterns, it can be concluded that the difference for the global (category psychotherapy alone or in combination) is due to 
the use of psychotherapy in combination with low-intensity treatments. 
Treatment with antidepressant pharmacotherapy. AD as global category, i.e. alone or in combination, differences in utiliza-
tion between groups cannot be confirmed. Approximately half of the patients with MMD received AD (54.4% in TAU and 49.6% in 
SCM), whereas more than 2/3 of patients with SD received AD (82.8% in TAU and 73.9% in SCM). 
For the subgroups of patients receiving AD only there is a difference in utilization between TAU and SCM: This difference is 
similar across severity groups (MMD: 20.3% TAU vs. 5.9% SCM; SD: 17.2% TAU vs. 7.2% SCM patients with AD only). However, due 
to the large and overlapping confidence interval in the SD group the difference is reliable only for the MMD group. 
Inpatient treatment. Inpatient care was initiated 12.6% less frequently in SCM than in TAU (21.5% TAU vs. 8.9% SCM pa-
tients with inpatient treatment). For the SD group, approx. 1/3 of patients in both conditions received inpatient care (39.1% TAU 
and 34.5% SCM patients). 
5. Discussion 




This subgroup analysis of a cluster-randomized controlled intervention trial suggests that SCM is effective for patients of 
different severity groups. Our primary strategy for data analysis (ITT analysis with replacement of missing values by the LOCF 
method) shows a significant effect regarding depressive symptom reduction for SCM in mildly to moderately depressed patients 
but not in severely depressed patients. However, the sensitivity analyses (ITT-analysis with MI replacement, the completer analy-
sis and pattern mixture model with control-based pattern imputation) do not confirm this result: According to these three sensi-
tivity analyses, there are significant effects for SCM in both severity groups. However, effect sizes for SCM are higher for mildly to 
moderately depressed patients compared to severely depressed patients. Given these slightly divergent results, a relevant pro-
portion of the differential effect of SCM for different severity groups in the LOCF analysis might be due to the high rate of selec-
tive dropouts in the group of severe depression patients, i.e. especially those treated in the SCM. A closer look at the dropouts in 
severely depressed patients reveals that most of them left the study immediately after study inclusion and did not contribute any 
other data except baseline assessment - neither regarding patient questionnaires nor the documentation data of their GPs. Re-
placing missing values by LOCF, i.e. by the baseline score, for a substantial percentage (46%) within the severely depressed pa-
tients in SCM might have led to an underestimation of effectiveness for this subgroup. Therefore, defining LOCF as primary strate-
gy of replacement of missing values when designing the study turns out to be unfavourable in the course of the trial revealing the 
(unexpected) the selective drop out between severity groups. Accordingly, when changing the replacement strategy and choosing 
MI replacement or pattern mixture model, SCM is also effective for severe depression. The differential effect sizes of stepped and 
collaborative care models with larger effects for mild to moderate patients are in line with those few outcome studies taking into 
account symptom severity of depression (Katon et al., 2002; Walker et al., 2000). Interestingly, this differential effect points in the 
reverse direction compared to results of meta analyses on placebo-controlled antidepressant trials suggesting an effect of AD only 
with increasing severity of depression symptoms (Fournier et al., 2010; Khan et al., 2002; Rabinowitz et al., 2016). However, this is 
not contradictory to the results of our study as we have not investigated a single treatment options such as antidepressant medi-
cation but a whole care model aiming at tailoring treatments to patients – and relying the treatment selection on guideline rec-
ommendations which are exactly based on the evidence on differential effects of antidepressant medication (among others). This 
has led to the algorithm within the SCM that in mild to moderate depression the first line treatment was (low intensity) psycho-
logical treatment - and not antidepressant medication. 
What might have caused the selective dropout in the severely depressed group in our study? We do not have any infor-
mation about the reasons for this. The severity of these patients’ depression and the associated symptom burden may have im-
peded their participation in data collection and staying in continuous contact with the responsible care providers, as SCM recom-
mends. Franx et al. report similar difficulties in adherence for patients with severe depression participating in stepped care (Franx 
et al., 2009). When severely depressed patients joined the SCM and were treated according to its concept, they benefitted signifi-
cantly more from treatment in SCM than patients in TAU, as shown in the completer analysis. 
However, even when taking into account the methodical uncertainty caused by the selective dropout, we did find - at least 
slightly - lower effect sizes for severely depressed patients in both SCM and TAU implicating that this group profits less from 
treatment than mildly to moderately depressed patients. This could be confirmed by all analyses (again with variation across pri-
mary analysis on the one hand and sensitivity analyses on the other hand) and is in line with findings of other studies that report 
better outcomes for non-severely depressed patients than for severely depressed patients (Franx et al., 2009; Katon et al., 2002; 
Walker et al., 2000). 
5.2 Differential treatment utilization 
The analysis of treatments received by patients during 12-month study participation provides important information for 
understanding the results of the differential outcomes and allows an insight into which treatments and interventions were actual-
ly implemented in SCM and routine care in the different subgroups. Overall, the results of the treatment utilization analysis are 
consistent with those of the effectiveness analysis: they help explain the higher benefit of the SCM for mildly to moderately de-
pressed patients in terms of adequate treatment allocation. The hypothesis that patients in SCM more often receive depression-
specific treatment and less often only GP consultations was confirmed. Additionally, a higher difference in these treatment utiliza-




comparison to severely depressed patients. This finding can partly be explained by the successful implementation of low intensity 
approaches as stand-alone treatment for mildly to moderately depressed patients. These treatments were additional intervention 
options GPs in SCM could use. However, this stand-alone application of low intensity treatments is adherent to the SCM concept 
only for mildly to moderately depressed patients, but not for severely depressed patients. However, the latter were also provided 
with only this treatment in 16% of the cases. Thus, these severely depressed patients were not treated in line with the SCM ra-
tional and with guidelines, and it can be assumed that they were undersupplied: for this group, the low intensity treatment did 
not facilitate the access to more intense treatments by introducing them into the health care system and motivating them for 
further treatment (vs. approx. 14% severely depressed patients who received an additional specific treatment, i.e. for whom the 
low intensity treatment succeeded in serving as “door opener”). This may explain the lower effect size of the effectiveness analy-
sis in the SCM for the subgroup of severely depressed patients, at least to a certain degree. The hypothesis of reduced AD use in 
SCM for mildly to moderately depressed patients in general could not be confirmed. The reason for this might be that the group 
of mild to moderate depression does not only consist of mildly but also of moderately depressed patients, for whom it would be 
adequate to apply AD treatment as alternative treatment option to PT. However, there were less mildly to moderately depressed 
patients in SCM who received nothing but AD treatment, i.e. these patients received additional psychological support or used a 
self-help approach. The hypothesis of a reduced proportion of inpatient treatments for mildly to moderately depressed patients 
in SCM was confirmed, as admission rates in SCM were less than half of those in TAU (9% vs. approx. 22%). This shows that the 
SCM offers the potential to avoid this intensive and also cost-intensive care form for patients with non-severe depression, while 
at the same time improving the outcome of this group, as effectiveness analysis show. 
The utilization data suggests that the focus of the GP in TAU lay on severely depressed patients while mildly to moderately 
depressed patients were more likely overlooked. This was different in SCM and implicates that the SCM holds potential to detect 
and improve the undersupply of mildly to moderately depressed patients. 
Again, as we refer to the same assessment in the analysis of utilization as in the outcome analyses (assessment at T3), the 
data base for utilization is broader for the mildly to moderately depressed group than for the severely depressed group, given the 
larger dropout rate of the latter. Therefore, comparisons within the severe depression group are less reliable due to the relatively 
small sample size and associated larger confidence intervals. However, referring to the patients who participated the whole study 
period of 12 months (completers) we were able to robustly report patterns of utilization. 
Limitations. The major limitation of these outcome and utilization analyses is the aforementioned high proportion of miss-
ing values in the subgroup of severely depressed patients. Therefore, our analyses are more robust for the mild to moderate than 
for the severely depressed group. In order to respond to this limitation we conducted sensitivity analyses in order to take into 
account this circumstance. A limitation of the analysis of utilization is that due to the kind of data assessment (i.e. retrospectively 
assessed utilization data reported by patients) it is not possible to deduce statements about the exact temporal sequence of 
treatments, stepping-up pattern and – especially important - the quality of the treatments patients received, e.g. the quality of 
type, dose and frequency of medication in pharmacotherapy. 
5.3 General discussion 
As both the differential outcome analyses with lower effect sizes for severely depressed patients in SCM and the treatment 
utilization analysis show, the particular challenge is to improve the care of severely depressed patients and to ensure more guide-
line-based care. Cases of severe depression are more complex and need more effort to implement guideline-adherent treatment. 
The results of our study suggest that certain interventions of the SCM especially for severe depression (e.g. combination of PT and 
AD) have not yet been implemented sufficiently and that there is need to improve the implementation of the SCM in line with its 
concept. A prior study analyzing the SCM patients of the same trial regarding treatment decisions and initial treatments reported 
consistent results: guideline-adherent treatment initiation was highest for mildly depressed patients and lowest for severely de-




The higher barriers in care delivery for severely depressed patients might be due to their higher symptom burden, which 
may affect treatment implementation. For example, the challenge to call a psychotherapist for an appointment may be higher for 
a severely depressed patient than for a mildly depressed patient who suffers from less symptoms of social withdrawal and hope-
lessness. Patients in severe crises might also be more ambivalent towards treatments and decide against a selected treatment 
even before beginning it, due to doubts and negative expectations and emotions. One implication of this finding for the improve-
ment of depression care could be the comprehensive implementation of closer systematic monitoring by the main care provider 
to check whether the patient receives the agreed-upon treatment and whether this leads to relevant symptom reduction or must 
be adapted. Another option would be the introduction of an even more systematic case management, which tracks and accom-
panies the patient throughout his or her treatment pathway. The conception of stepped and collaborative care imply this kind of 
support – however, implementing this properly within the complex intervention remains a crucial task. 
6. Conclusions 
In conclusion, access to treatment, triage and the coordination of pathways remains an area with challenges for which 
stepped care promises to offer a means of improvement for different severity levels of depression. An adequate implementation 
of the approach demands much effort by providers, patients and stakeholders (the latter for creating the adequate conditions and 
incentives within the health care system) and appears to be crucial for ensuring processes and – by this – improved outcome for 
patients. 
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Figure 1: Participant flowchart according to the cluster-randomized CONSORT statement (40). Legend: GP: 
General practitioner; MMD: mild to moderate depression; SD: severe depression; AFA: available for analy-
sis; LOV: last observed value; ITT: Intention-to-treat 
Table 1: Baseline characteristics on patient level in SCM1 and TAU2 
 Group 




TAU2 (n=113) SCM1 (n=186) TAU2 (n=55) 
Age (M (Standard Deviation)) 43.4 (13.9) 48.9 (16.4) 39.4 (12.2) 38.9 (10.8) 




Education level (% (n))     
 Secondary general school3 18.8 (72) 32.7 (37) 23.7 (44) 23.6 (13) 
 Intermediate secondary school4 29.0 (111) 23.0 (26) 24.7 (46) 32.7 (18) 
 High school5 25.8 (99) 23.9 (27) 23.7 (44) 18.2 (10) 
 University or technical college degree 17.5 (67) 10.6 (12) 7.5 (14) 9.1 (5) 
 No school degree 1.6 (6) 3.5 (4) 3.2 (6) 1.8 (1) 
 Missing 7.3 (28) 6.2 (7) 17.2 (32) 14.5 (8) 
Employment status (% (n))     
 No employment 22.7 (87) 25.7 (29) 32.8 (61) 40.0 (22) 
 Minor employment 3.1 (12) 4.4 (5) 3.2 (6) 1.8 (1) 
 Part-time employment 20.9 (80) 16.8 (19) 14.0 (26) 14.5 (8) 
 Full-time employment 44.4 (170) 38.9 (44) 35.5 (66) 34.5 (19) 
 Missing  8.9 (34) 14.2 (16) 14.5 (27) 9.1 (5) 
Living in partnership (% (n)) 58.2 (223) 52.2 (59) 45.7 (85) 52.7 (29) 
 Missing 7.0 (27) 8.0 (9) 14.0 (26) 9.1 (5) 
PHQ-9 at baseline (M (SD)) 13.3 (3.9) 11.8 (4.0) 19.5 (3.1) 18.7 (3.2) 
1SCM = Stepped collaborative care model (intervention group); 2TAU = Treatment as usual (control group); 3German: Hauptschule (9 years of 
education); 4German: Realschule (10 years); 5German: Gymnasium (13 years). 
Table 2: Results of the primary and sensitivity analyses on differential treatment outcome of SCM1 at T3. 
























































































































0.093 0.25 0.036 





























0.028 0.47 0.339 





























0.004 0.47 0.332 





























0.001 0.49 0.34 
1SCM: Stepped and collaborative care; 2 TAU: Treatment as usual. 
Table 3: Treatment utilization for different patient groups in SCM1 or TAU2 within 12-month study participa-
tion 
ntervention % (n) [confidence 
nterval] 






TAU n=79 SCM n=69 TAU n=29 




























bination) [87;93] [91;99] [86;94] [89;99] [82;97] [82;100] 
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no information (missing data) 23 (128) 20 (33) 12 (46) 14 (16) 44 (82) 31 (17) 
1SCM: Stepped and collaborative care; 2 TAU: Treatment as usual; 3 n.a.: not assessed; 4 Any outpatient depression-specific treatment: low-
intensity and/or psychotherapy and/or antidepressant pharmacotherapy; 5 MMD: mildly to moderately depressed patients; 6 SD: severely de-
pressed patients; bold numbers: confidence intervals that do not overlap between SCM and TAU within the total sample and within each severi-
ty group. 
 
฀฀฀฀฀฀฀฀฀
